bIosimilar of aDalimumab, an European evAluation

Inclusion Criteria: 1. Age ≥18 years, male or female. 2. Patients diagnosed with one chronic inflammatory rheumatological (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) or chronic inflammatory bowel (Crohn's disease, ulcerative colitis) diseases. 3. Patients who have been switched to FK adalimumab from the reference product (Humira®) or another adalimumab biosimilar. 4. Patients who have been prescribed FK adalimumab according to the SmPC prior to the inclusion. 5. Patients able to understand and complete the study questionnaires in local language during the study visits. 6. Patients willing to sign informed consent to meet data protection requirements Exclusion Criteria: 1. Unwillingness to provide written informed consent. 2. Patients participating or expected to participate in any randomised clinical trial during their treatment with FK adalimumab. 3. Patients not expected to be available for study visits during 12 months.